Extendicare Inc
TSX:EXE

Watchlist Manager
Extendicare Inc Logo
Extendicare Inc
TSX:EXE
Watchlist
Price: 14.73 CAD 1.45% Market Closed
Market Cap: 1.2B CAD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
0%
Revenue
Forecast
+5%
Operating Income
Forecast
+25%
Net Income
Forecast
+4%

Wall Street
Price Targets

EXE Price Targets Summary
Extendicare Inc

Wall Street analysts forecast EXE stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EXE is 14.66 CAD with a low forecast of 13.13 CAD and a high forecast of 17.33 CAD.

EXE Lowest Forecast
Wall Street Target
13.13 CAD
11% Downside
EXE Average Forecast
Wall Street Target
14.66 CAD
0% Downside
EXE Highest Forecast
Wall Street Target
17.33 CAD
18% Upside
Lowest
Price Target
13.13 CAD
11% Downside
Average
Price Target
14.66 CAD
0% Downside
Highest
Price Target
17.33 CAD
18% Upside
Extendicare Inc Competitors:
Price Targets
ENSG
Ensign Group Inc
13% Upside
ARDT
Ardent Health Partners Inc
33% Upside
M12
M1 Kliniken AG
82% Upside
CVSG
CVS Group PLC
20% Upside
ENSG
Ensign Group Inc
13% Upside
ARDT
Ardent Health Partners Inc
33% Upside
M12
M1 Kliniken AG
82% Upside
CVSG
CVS Group PLC
20% Upside
4013
Dr Sulaiman Al-Habib Medical Services Group Co
12% Upside
A
AEVS
Aevis Victoria SA
13% Upside
H
301267
Huaxia Eye Hospital Group Co Ltd
27% Upside
BH
Bumrungrad Hospital PCL
38% Upside

Revenue
Forecast

Revenue Estimate
Extendicare Inc

For the last 8 years the compound annual growth rate for Extendicare Inc's revenue is 4%. The projected CAGR for the next 3 years is 5%.

4%
Past Growth
5%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Extendicare Inc

For the last 8 years the compound annual growth rate for Extendicare Inc's operating income is 8%. The projected CAGR for the next 3 years is 25%.

8%
Past Growth
25%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Extendicare Inc

For the last 8 years the compound annual growth rate for Extendicare Inc's net income is 10%. The projected CAGR for the next 3 years is 4%.

10%
Past Growth
4%
Estimated Growth
Estimates Accuracy
34%
Average Beat
What are analyst estimates?

See Also

Summary
EXE intrinsic value, competitors valuation, and company profile.
DCF Valuation
EXE stock valuation using Discount Cash Flow valuation method.
Relative Valuation
EXE stock valuation using valuation multiples.
Wall Street Estimates
EXE price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
EXE stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is EXE's stock price target?
Price Target
14.66 CAD

According to Wall Street analysts, the average 1-year price target for EXE is 14.66 CAD with a low forecast of 13.13 CAD and a high forecast of 17.33 CAD.

What is Extendicare Inc's Revenue forecast?
Projected CAGR
5%

For the last 8 years the compound annual growth rate for Extendicare Inc's revenue is 4%. The projected CAGR for the next 3 years is 5%.

What is Extendicare Inc's Operating Income forecast?
Projected CAGR
25%

For the last 8 years the compound annual growth rate for Extendicare Inc's operating income is 8%. The projected CAGR for the next 3 years is 25%.

What is Extendicare Inc's Net Income forecast?
Projected CAGR
4%

For the last 8 years the compound annual growth rate for Extendicare Inc's net income is 10%. The projected CAGR for the next 3 years is 4%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 255,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.